RBC Bioscience (ROCO:6848) Total Assets: NT$724.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6848 RBC Bioscience Corp ROCO:6848
76 GF Score
Price NT$19.70
GF Value NT$19.91
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is RBC Bioscience Total Assets?

RBC Bioscience ROCO:6848 -3.90% 76 Total Assets is NT$724.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review.

RBC Bioscience's Total Assets for the quarter that ended in Dec. 2025 was NT$724.5 Mil.

During the past 12 months, RBC Bioscience's average Total Assets Growth Rate was 0.30% per year. During the past 3 years, the average Total Assets Growth Rate was -1.30% per year. During the past 5 years, the average Total Assets Growth Rate was 10.50% per year.

During the past 9 years, RBC Bioscience's highest 3-Year average Total Assets Growth Rate was 71.30%. The lowest was -1.70%. And the median was 46.85%.

Total Assets is connected with ROA %. RBC Bioscience's annualized ROA % for the quarter that ended in Dec. 2025 was 3.34%. Total Assets is also linked to Revenue through Asset Turnover. RBC Bioscience's Asset Turnover for the quarter that ended in Dec. 2025 was 0.15.

RBC Bioscience  (ROCO:6848) Total Assets Explanation

Total Assets is connected with ROA %.

RBC Bioscience's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=24.748/( (757.615+724.493)/ 2 )
=24.748/741.054
=3.34 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

RBC Bioscience's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=112.011/( (757.615+724.493)/ 2 )
=112.011/741.054
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

RBC Bioscience Total Assets Related Terms

RBC Bioscience Total Assets Historical Data

* Premium members only.

The historical data trend for RBC Bioscience's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RBC Bioscience Total Assets Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only 847.60 790.55 753.79 763.88 724.49

RBC Bioscience Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 753.79 771.71 763.88 757.62 724.49
ROCO:6848
76GF Score
RBC Bioscience Corp ROCO:6848
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RBC Bioscience Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

RBC Bioscience's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=268.538+455.955
=724.5

RBC Bioscience's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=268.538+455.955
=724.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of NT$724.5 Mil mean?
RBC Bioscience (ROCO:6848) has a Total Assets of NT$724.5 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on RBC Bioscience and its competitors.
Is RBC Bioscience's Total Assets too high?
RBC Bioscience's current Total Assets is NT$724.5 Mil. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Total Assets compare to VRTX and REGN?
RBC Bioscience's Total Assets of NT$724.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on RBC Bioscience and its competitors. RBC Bioscience's current Total Assets is NT$724.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$19.70 — trading 1.1% below its estimated fair value. The current Total Assets is NT$724.5 Mil. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Total Assets is NT$724.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RBC Bioscience (ROCO:6848) Overvalued in 2026?

Based on GuruFocus' analysis, RBC Bioscience stock appears to be undervalued. The current stock price of NT$19.70 is trading 1.1% below its estimated GF Value™ of NT$19.91. GuruFocus considers RBC Bioscience to be Fairly Valued.

Key valuation signals for ROCO:6848:

  • Total Assets: NT$724.5 Mil
  • GF Value™: NT$19.91 vs. price of NT$19.70 (1.1% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RBC Bioscience Business Description

Address No. 15, Qiaohe Road, 15th Floor, Zhonghe District, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score

Get the complete analysis for ROCO:6848

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.70
Price
NT$19.91
GF Value